HER2, also known as ERBB2, is a well-established oncogene implicated in a variety of malignancies, most notably breast and gastric cancers. However, its role in lung cancer—particularly NSCLC—has emerged more recently, revealing a niche yet vital subset of patients whose tumors harbor activating mutations or amplifications of this gene. The current investigation focuses on a cohort of 13 patients from Northeastern Brazil with identified HER2 mutations in NSCLC tumors, drawing attention not only to the presence of these mutations but also to their extensive genomic interplay with other oncogenic drivers. This nuanced molecular profiling propels the study beyond mere identification, providing a window into the intricate mutational landscapes that drive tumor behavior in this demographic.

The cohort ranged widely in age from 34 to 82 years, with a slight female predominance and nearly half classified as non-smokers—a noteworthy epidemiological feature given the traditionally strong association of lung cancer with tobacco exposure. Morphologically, the tumors exhibited classic adenocarcinoma patterns, with histopathological examination detailing mixed acinar and papillary architectures. Notably, immunohistochemical analysis revealed low-level HER2 protein expression despite DNA-level mutations, a finding underscored by dual in situ hybridization techniques confirming the absence of gene amplification. These subtleties emphasize the complexity inherent in relying solely on protein expression or amplification status to define HER2 involvement in NSCLC.

Genomic interrogation uncovered a rich tapestry of co-occurring mutations. Alterations in TP53, KRAS, and STK11 genes frequently accompanied HER2 mutations, underscoring the multifaceted oncogenic networks that coalesce within these tumors. Among the HER2 mutations identified, exon 20 insertions predominated, conforming to a hotspot region known to induce constitutive activation of the HER2 tyrosine kinase domain. This mechanistic detail furthers our understanding of how these mutations contribute to malignant transformation and progression in NSCLC, offering tangible targets for pharmacologic intervention.

From a therapeutic standpoint, the study paints a sobering picture of current clinical realities. Despite the availability of promising HER2-targeted agents, notably trastuzumab deruxtecan (T-DXd)—the first FDA-approved drug to demonstrate robust efficacy in HER2-mutant NSCLC—the majority of patients in this cohort did not receive targeted therapy. Instead, conventional modalities such as surgery, chemotherapy, and immunotherapy were predominantly employed, reflecting both access barriers and the necessity for heightened awareness and infrastructure to implement molecular testing and precision medicine strategies in low-resource settings.

The disparity in treatment outcomes was stark. Survival times ranged widely, with some individuals achieving protracted remission extending several years post-diagnosis, while others succumbed rapidly, within months. This heterogeneity not only mirrors the underlying biological complexity revealed by the molecular data but also highlights the critical importance of early, accurate diagnosis paired with the optimal therapeutic approach. The authors rightly advocate for integrating comprehensive molecular profiling into routine diagnostic algorithms, advocating a tiered strategy that begins with baseline screening for actionable mutations followed by more sophisticated genomic analyses when warranted.

Importantly, this study addresses a significant gap in cancer research by spotlighting a population that has been historically marginalized in genomic and clinical oncology research. Latin America, and particularly regions like Northeastern Brazil, are underrepresented in large-scale cancer genomics initiatives. This lack of representation constrains global understanding of disease biology and impedes equitable drug development and clinical guideline formulation. By elucidating the unique molecular features and clinical patterns of NSCLC with HER2 mutations in this geographic and ethnic context, the research elevates the imperative for inclusive, region-specific cancer research endeavors.

The study’s findings also provoke reflection on the molecular diagnostic tools currently available and their performance in diverse populations. The relatively low HER2 protein expression despite the presence of activating mutations invites reconsideration of reliance on immunohistochemistry (IHC) alone for patient selection in clinical trials and therapeutic decision-making. Dual in situ hybridization assays and next-generation sequencing (NGS) emerge as indispensable adjuncts to uncover the full spectrum of HER2 alterations and accompanying mutations, thereby refining patient stratification and enhancing personalized medicine.

Moreover, the research team’s proposal of a tiered diagnostic framework tailored to resource availability and clinical need represents a pragmatic model with potential applicability far beyond the study’s geographic confines. Starting with cost-effective screening methods and escalating to detailed genomic profiling as indicated, such an approach could democratize access to precision oncology and improve clinical outcomes through appropriate therapeutic sequencing.

This research further underscores the transformative potential of novel HER2-directed therapies like trastuzumab deruxtecan, which have demonstrated significant response rates and progression-free survival benefits in HER2-mutant NSCLC. However, the limited use of these agents within the studied cohort delineates pressing access issues. Addressing these gaps necessitates concerted efforts to build infrastructure, training, and healthcare policies that promote molecular testing and equitable distribution of targeted treatments, especially in low- and middle-income countries.

Future directions prompted by this work include expanding cohort sizes to validate findings and unravel prognostic implications of different HER2 mutation subtypes. Additionally, longitudinal studies integrating clinical outcomes with molecular profiles will be crucial to ascertain predictive biomarkers of treatment response and resistance mechanisms. Ultimately, these endeavors will inform guidelines that are both globally relevant and locally adaptable.

In addition to clinical and molecular insights, the study carries socio-ethical ramifications, emphasizing the need for global oncology communities to prioritize underrepresented populations to achieve health equity. The research thus serves as a clarion call to dismantle barriers that have historically limited access to cutting-edge cancer diagnostics and therapeutics worldwide.

In conclusion, this seminal investigation charts critical molecular and clinical terrain by decoding the complex landscape of HER2-mutated NSCLC in Northeastern Brazil. By highlighting the intricate genomic interplay, diagnostic hurdles, treatment disparities, and the pressing need for expanded molecular profiling and targeted therapy access, it propels the field toward more inclusive, precise, and effective lung cancer management strategies. The study not only enriches scientific understanding but also reinforces the broader imperative of global health equity in oncology research and care.

Article Title: Molecular landscape of HER2-mutated non-small cell lung cancer in Northeastern Brazil: Clinical, histopathological, and genomic insights

News Publication Date: 17-Jun-2025

Web References:

• Oncotarget Volume 16: https://www.oncotarget.com/archive/v16/
• DOI: 10.18632/oncotarget.28737

Image Credits: Copyright: © 2025 Nogueira et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0).

Keywords: cancer, HER2 mutation, NSCLC, lung cancer, targeted therapy, genomic profiling

Non-small-cell lung cancer remains a leading cause of cancer-related mortality worldwide, and Asia, particularly regions such as Taiwan, is disproportionately affected by diverse molecular subtypes that necessitate tailored therapeutic approaches. The study’s retrospective design encompassed 478 Taiwanese NSCLC patients, spanning five years, thereby providing unparalleled insight into the genetic heterogeneity of the population. Using the OFA platform, researchers systematically interrogated key driver mutations and complex genomic rearrangements, aiming to optimize clinical diagnostics and patient management.

One of the most striking outcomes of the investigation is the platform’s high success rate, successfully sequencing 80.5% of patient specimens. Achieving such a rate in real-world clinical samples is notable, as variables like tumor cell percentage, specimen source, and the age of formalin-fixed, paraffin-embedded (FFPE) tissue blocks are known to impact sequencing quality and accuracy. The study meticulously analyzed these factors, underscoring their pivotal roles in ensuring reliable NGS results. This highlights the importance of pre-analytical considerations in clinical sequencing workflows.

Performance metrics of the OFA further attest to its robustness. Sequencing runs demonstrated exceptional on-target alignment, reaching an average of 97.0%, an indicator that the assay efficiently captures relevant genomic regions with minimal off-target noise. Uniformity, a critical measure reflecting even coverage across targeted amplicons, averaged 94.7%, while coverage depths exceeded 500× for over 98% of these regions. Together, these metrics reveal the assay’s capacity to generate high-quality, reproducible genetic data crucial for clinical decision-making.

Within the successfully analyzed cohort, the prevalence of pathogenic or likely pathogenic variants was remarkably high at 86.8%, revealing the profound molecular diversity resident within Asian NSCLC patients. Mutations were cataloged across various classes: single nucleotide variants (SNVs) and small insertions/deletions (Indels) dominated, representing 78.4% of genetic alterations detected. Copy number variations (CNVs) were also prominent, appearing in 41.6% of patients, illustrating the complex genomic rearrangements contributory to tumorigenesis. Notably, the assay could detect rarer events such as exon skipping and gene fusions, which are increasingly recognized as vital oncogenic drivers amenable to targeted therapies.

The spectrum of actionable driver mutations detected corroborates and extends existing epidemiological data on NSCLC in Asian populations. EGFR mutations were observed in 46.2% of cases, reaffirming their status as the most prevalent oncogenic alterations in this demographic. The presence of other hotspots, including KRAS (9.4%), ERBB2 (6.8%), and BRAF (2.3%) mutations, paints a multifaceted picture of tumor biology. Additionally, detecting ALK fusions (4.4%) and MET exon 14 skipping alterations (2.3%) adds to a growing catalog of genomic aberrations with approved targeted therapies or drugs under clinical evaluation.

A particularly intriguing finding concerns the KRAS G12C mutation, present in 2.8% of the cohort. This mutation has recently garnered significant clinical interest due to the development of specific inhibitors, marking a shift in previously undruggable targets towards actionable vulnerabilities. Its identification in an Asian NSCLC population signals the importance of including this biomarker in routine molecular profiling, enabling a broader patient base to benefit from emerging treatments.

The study’s implications extend beyond biomarker detection; it affirms the Oncomine Focus Assay’s clinical utility in integrating genomic analyses into routine care. The combination of robust performance metrics and comprehensive variant detection capabilities offers oncologists a reliable tool to tailor therapies, navigate resistance mechanisms, and monitor disease progression. By validating this platform in a real-world setting, the research bridges the gap between technological innovation and tangible patient outcomes.

Moreover, the study addresses a gap in the literature concerning the clinical utility of different NGS platforms in NSCLC. Although multiple sequencing approaches exist, few have been comprehensively assessed within large, ethnically homogeneous cohorts, limiting the generalizability of findings. Through its rigorous evaluation of sequencing success determinants and genetic landscapes, this research provides a template for integrating targeted NGS into Asian clinical oncology practices, where unique genetic profiles may influence therapeutic responsiveness.

The integration of NGS into clinical workflows also prompts considerations surrounding tissue handling, sample quality, and turnaround times, all critical factors in delivering timely and actionable results for cancer patients. This study’s recognition of FFPE block age and tumor cell content as key modulators of NGS success underlines the necessity for standardized protocols and quality control measures to maximize assay efficacy in diverse clinical environments.

Furthermore, the detection of diverse genetic alterations, including gene fusions such as ROS1, RET, and the rare NTRK1 fusions, highlights the evolving paradigm in lung cancer treatment. The emergence of targeted inhibitors for these molecular events has transformed NSCLC care, offering patients personalized therapeutic options that improve outcomes and reduce systemic toxicity. The study reinforces the need for inclusive molecular panels capable of capturing the full gamut of oncogenic drivers.

As targeted therapies become more available and guidelines increasingly recommend molecular profiling, the scalability and robustness of assays like the OFA assume critical importance. The successful application of targeted NGS in a large-scale real-world cohort validates its role in supporting precision medicine. This alignment of diagnostic innovation with clinical needs promises to accelerate the adoption of bespoke therapies, ultimately contributing to improved survival and quality of life for patients.

In conclusion, this comprehensive study elucidates the value of targeted next-generation sequencing in unraveling the complex mutational architecture of Asian NSCLC. By demonstrating high analytical performance and detailed molecular insights, it underscores the transformative potential of precision oncology in regions with distinct genetic epidemiology. Such advancements pave the way for enhanced therapeutic stratification, improved patient outcomes, and a future where lung cancer care is increasingly individualized and effective.

Subject of Research: Targeted next-generation sequencing for molecular variant identification in Asian non-small-cell lung cancer patients

Article Title: Real-world application of targeted next-generation sequencing for identifying molecular variants in Asian non-small-cell lung cancer

Article References:
Wang, FY., Yeh, YC., Lin, SY. et al. Real-world application of targeted next-generation sequencing for identifying molecular variants in Asian non-small-cell lung cancer. BMC Cancer 25, 715 (2025). https://doi.org/10.1186/s12885-025-14016-z

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-14016-z